Dulaglutide
- Generic Name
- Dulaglutide
- Brand Names
- Trulicity
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 923950-08-7
- Unique Ingredient Identifier
- WTT295HSY5
- Background
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was appro...
- Indication
Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular r...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin
- Conditions
- Interventions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Corporacion Parc Tauli
- Target Recruit Count
- 116
- Registration Number
- NCT04829903
- Locations
- 🇵🇰
Zainab Khan, Lahore, Punjab, Pakistan
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 591
- Registration Number
- NCT04809220
- Locations
- 🇯🇵
Ota Diabetes Internal Medicine Clinic, Nagano, Japan
🇯🇵Heiwadai Hospital, Miyazaki, Japan
🇯🇵Hachioji Diabetes Clinic, Hachioji, Tokyo, Japan
Effects of Glucagon-Like Peptide-1 Analogs on Sexuality
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 26
- Registration Number
- NCT04687514
- Locations
- 🇨🇭
University Hospital Basel, Endocrinology, Diabetes and Metabolism, Basel, Switzerland
A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 67
- Registration Number
- NCT04641312
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
🇩🇪Profil Mainz, Mainz, Germany
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 291
- Registration Number
- NCT04591626
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou Shi, Henan, China
🇨🇳The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi, Henan, China
🇨🇳Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of LY3493269 in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT04515576
- Locations
- 🇺🇸
Miami Research Associates, Miami, Florida, United States
🇺🇸Clinical Trials of Texas, Inc., San Antonio, Texas, United States
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04466904
- Locations
- 🇨🇳
China Japan Friendship Hospital, Beijing, China
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
- Conditions
- Interventions
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2024-12-05
- Target Recruit Count
- 23
- Registration Number
- NCT04387201
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13299
- Registration Number
- NCT04255433
- Locations
- 🇦🇺
GenesisCare, Murdoch, Western Australia, Australia
🇺🇸Valley Research, Fresno, California, United States
🇺🇸AMCR Institute, Escondido, California, United States
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
- Conditions
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 104
- Registration Number
- NCT04189848
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.